Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SLN
stocks logo

SLN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
5.63M
+289.56%
-0.148
-79.68%
3.03M
+2043.57%
-0.170
-71.67%
Estimates Revision
The market is revising Downward the revenue expectations for Silence Therapeutics plc (SLN) for FY2025, with the revenue forecasts being adjusted by -58.63% over the past three months. During the same period, the stock price has changed by 25.31%.
Revenue Estimates for FY2025
Revise Downward
down Image
-58.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+81.1%
In Past 3 Month
Stock Price
Go Up
up Image
+25.31%
In Past 3 Month
Wall Street analysts forecast SLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLN is 75.00 USD with a low forecast of 75.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLN is 75.00 USD with a low forecast of 75.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.130
sliders
Low
75.00
Averages
75.00
High
75.00
Current: 7.130
sliders
Low
75.00
Averages
75.00
High
75.00
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$75
2025-03-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$75
2025-03-07
Reiterates
Strong Buy
Reason
Morgan Stanley
Michael Ulz
Buy
Maintains
$49 → $45
2025-03-05
Reason
Morgan Stanley
Michael Ulz
Price Target
$49 → $45
2025-03-05
Maintains
Buy
Reason
BMO Capital
Kostas Biliouris
Buy
Maintains
$67 → $25
2025-03-04
Reason
BMO Capital
Kostas Biliouris
Price Target
$67 → $25
2025-03-04
Maintains
Buy
Reason
Goldman Sachs
Richard Law
Strong Sell
Maintains
$6 → $4
2025-03-04
Reason
Goldman Sachs
Richard Law
Price Target
$6 → $4
2025-03-04
Maintains
Strong Sell
Reason
Goldman Sachs
Richard Law
Strong Sell
Initiates
$6
2025-02-11
Reason
Goldman Sachs
Richard Law
Price Target
$6
2025-02-11
Initiates
Strong Sell
Reason
Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics with a Sell rating and $6 price target.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$75
2025-02-03
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$75
2025-02-03
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Silence Therapeutics PLC (SLN.O) is -7.51, compared to its 5-year average forward P/E of -14.29. For a more detailed relative valuation and DCF analysis to assess Silence Therapeutics PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-14.29
Current PE
-7.51
Overvalued PE
-0.68
Undervalued PE
-27.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.62
Undervalued EV/EBITDA
-12.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
27.14
Current PS
0.00
Overvalued PS
54.09
Undervalued PS
0.19
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SLN News & Events

Events Timeline

(ET)
2025-11-06
09:04:02
Silence Therapeutics announces Q3 earnings per share of 15 cents, below consensus estimate of 21 cents.
select
2025-10-23 (ET)
2025-10-23
07:36:10
Silence Therapeutics finishes enrolling patients for SANRECO study.
select
2025-08-07 (ET)
2025-08-07
08:30:31
Silence Therapeutics reports Q2 EPS (19c), consensus (21c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-04NASDAQ.COM
Monday's Underperformers: Auto Dealerships and Biotechnology Shares

  • Biotechnology Sector Performance: Biotechnology shares are down approximately 2.1% on Monday, with notable declines from Emergent BioSolutions and Silence Therapeutics, which fell by 15.4% and 8.1%, respectively.

  • Market Context: The decline in biotechnology stocks is part of a broader market trend, with auto dealerships also lagging behind on the same day.

  • Source Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.

  • Video Content: A video segment highlights the sector laggards, specifically focusing on auto dealerships and biotechnology stocks.

[object Object]
Preview
4.0
09-16Benzinga
HC Wainwright & Co. Affirms Buy Rating for Silence Therapeutics, Keeps $75 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
9.5
08-07Newsfilter
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

  • Divesiran Development: Silence Therapeutics presented promising data on divesiran as a first-in-class siRNA for Polycythemia Vera (PV) at the EHA 2025, showing effective hematocrit control and minimal need for phlebotomies, with Phase 2 trial enrollment expected to complete by year-end 2025.

  • Financial Overview: The company reported a net loss of $27.4 million for Q2 2025, with cash reserves of approximately $114.2 million projected to fund operations through 2028, while R&D expenses increased due to advancing clinical trials.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Silence Therapeutics PLC (SLN) stock price today?

The current price of SLN is 7.13 USD — it has increased 12.64 % in the last trading day.

arrow icon

What is Silence Therapeutics PLC (SLN)'s business?

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

arrow icon

What is the price predicton of SLN Stock?

Wall Street analysts forecast SLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLN is 75.00 USD with a low forecast of 75.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Silence Therapeutics PLC (SLN)'s revenue for the last quarter?

Silence Therapeutics PLC revenue for the last quarter amounts to 159.00K USD, decreased -89.29 % YoY.

arrow icon

What is Silence Therapeutics PLC (SLN)'s earnings per share (EPS) for the last quarter?

Silence Therapeutics PLC. EPS for the last quarter amounts to -0.15 USD, decreased -40.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Silence Therapeutics PLC (SLN)'s fundamentals?

The market is revising Downward the revenue expectations for Silence Therapeutics plc (SLN) for FY2025, with the revenue forecasts being adjusted by -58.63% over the past three months. During the same period, the stock price has changed by 25.31%.
arrow icon

How many employees does Silence Therapeutics PLC (SLN). have?

Silence Therapeutics PLC (SLN) has 116 emplpoyees as of December 05 2025.

arrow icon

What is Silence Therapeutics PLC (SLN) market cap?

Today SLN has the market capitalization of 336.49M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free